Viridian Therapeutics Cash Flow Statement
NASDAQ: VRDNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
18.66+0.32 (+1.74%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Viridian Therapeutics free cash flow
In fiscal 2025, Viridian Therapeutics generated -$276.4 million of operating cash flow and spent $495,000 on capital expenditures. That left free cash flow of -$276.9 million, a free-cash-flow margin of -390.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Viridian Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -342.60M | -269.95M | -237.73M | -129.87M | -79.41M | -110.72M | -41.87M | -32.70M | -26.51M | -17.27M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 460.00K | 540.00K | 522.00K | 255.00K | 120.00K | 239.00K | 288.00K | 281.00K | 308.00K | 341.00K |
| Stock-Based Compensation | 44.30M | 42.15M | 67.17M | 19.77M | 14.46M | 3.65M | 3.97M | 3.68M | 2.41M | 198.00K |
| Change in Working Capital | 23.03M | 9.31M | -9.71M | 15.61M | 2.17M | 4.53M | 1.65M | 1.94M | -4.47M | 1.66M |
| Operating Cash Flow | -276.39M | -232.32M | -184.17M | -93.84M | -54.58M | -29.78M | -36.06M | -26.84M | -28.17M | -14.76M |
| Capital Expenditures | -495.00K | -511.00K | -898.00K | -797.00K | -338.00K | -42.00K | -84.00K | -445.00K | -246.00K | -250.00K |
| Investing Cash Flow | -37.56M | -228.65M | -94.25M | -115.13M | -74.29M | -50.48M | 28.23M | -29.91M | 1.03M | -250.00K |
| Share Repurchases | — | — | — | — | — | — | — | — | — | -2.00K |
| Debt Issued | 28.88M | 0 | 15.00M | 5.00M | — | — | — | — | — | — |
| Financing Cash Flow | 426.74M | 457.74M | 225.67M | 322.24M | 125.28M | 101.31M | 70.00K | 41.92M | 52.47M | 15.87M |
| Net Change in Cash | 112.79M | -3.23M | -52.75M | 113.28M | -3.60M | 21.05M | -7.76M | -14.84M | 25.34M | 869.00K |
| Free Cash Flow | -276.89M | -232.83M | -185.07M | -94.64M | -54.92M | -29.82M | -36.14M | -27.29M | -28.41M | -15.01M |
This table shows 10 annual periods of Viridian Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow VRDN's reporting calendar. What is a cash flow statement?